Strategic partnerships Exicure has demonstrated activity in co-development agreements, including a collaboration with Adbiotech for Burixafor (GPC-100). This indicates openness to external partnerships and combination therapy explorations, representing potential sales opportunities in collaborative R&D, licensing, or milestone-driven deals.

NSF & CNS focus The lead program targets SCN9A (Nav1.7) for non-opioid pain and other CNS disorders with high unmet needs such as Huntington’s, Angelman, Batten disease, spinocerebellar ataxia, and sporadic ALS. This creates cross-sell potential for CNS target validation services, oligonucleotide chemistry capabilities, and platform-based discovery services.

Early-stage engagement As an early-stage biotechnology with in-house discovery and high-throughput synthesis capability, Exicure could benefit from bundled service agreements, pilot collaborations, or technology licensing to accelerate candidate screening for potential partners seeking rapid lead generation.

Nasdaq readiness Recent Nasdaq notices regarding minimum stockholders’ equity and board changes signal ongoing corporate governance and financial stabilization needs. This may present timing considerations for equity financing conversations, strategic partnerships, or investor relations-led collaborations aligned with a growth plan.

Co-development momentum Co-development activity with a Korea-based partner signals appetite for international collaboration. There is potential to explore regional licensing, joint ventures, or co-funded trials, especially in markets where CNS and hematologic therapeutic exploration aligns with Exicure’s oligonucleotide platform.